80 FR 31042 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 80, Issue 104 (June 1, 2015)
Food and Drug Administration
Federal Register Volume 80, Issue 104 (June 1, 2015)
| Page Range | 31042-31048 | |
| FR Document | 2015-13102 |
[Federal Register Volume 80, Number 104 (Monday, June 1, 2015)] [Notices] [Pages 31042-31048] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-13102] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-N-1960] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by July 1, 2015. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-0291. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, PRAStaff@fda.hhs.gov. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. MedWatch: The FDA Medical Products Reporting Program OMB Control Number 0910-0291--Extension I. Background To ensure the marketing of safe and effective products, it is critical that postmarketing adverse outcomes and product problems are reported for all FDA-regulated human healthcare products, including drugs (prescription and nonprescription), biologics, medical devices, dietary supplements and other special nutritional products (e.g. infant formula and medical foods), and cosmetics. To facilitate reporting on human medical products (except vaccines) during their postapproval and marketed lifetimes, three forms (collectively known as the MedWatch forms) are available from the Agency. Form FDA 3500 is intended to be used for voluntary (i.e., not mandated by law or regulation) reporting by healthcare professionals. Form FDA 3500B is written in plain language and is intended to be used for voluntary reporting (i.e., not mandated by law or regulation) by consumers (i.e., patients and their caregivers). Form FDA 3500A is used for mandatory reporting (i.e., required by law or regulation). When FDA receives this information from healthcare professionals, patients, or consumers, the report becomes data that will be used to assess and evaluate the risk associated with the product. FDA will then take whatever action is necessary to reduce, mitigate, or eliminate the public's exposure to the risk through regulatory and public health interventions. Authorizing Statutes and Codified Regulations The Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 353b, 355, 360i, 360l, and 393) and the Public Health Service Act (42 U.S.C. 262) represent the statutory authority for the FDA to collect mandatory adverse event reports from regulated industry on medical products once approved for marketing to monitor the safety of drugs, biologics, medical devices, and dietary [[Page 31043]] supplements. There are no laws or regulations mandating the postmarket reporting for medical foods, infant formula, cosmetics, or tobacco products, and the reporting for these products is done voluntarily. Requirements regarding mandatory reporting of adverse events or product problems have been codified in parts 310, 314, 600, and 803 (21 CFR 310, 314, 600, and 803), specifically Sec. Sec. 310.305, 314.80, 314.98, 600.80, 803.30, 803.50, 803.53, 803.56, and specified in sections 503B, 760, and 761 (21 U.S.C. 379aa and 379aa-1) of the FD&C Act. Mandatory reporting of adverse reactions for human cells, tissues, and cellular- and tissue-based products (HCT/Ps) has been codified in 21 CFR 1271.350. II. Use of Form 3500 (Voluntary Reporting) This voluntary version of the form may be used by healthcare professionals to submit all reports not mandated by Federal law or regulation. Individual health professionals are not required by law or regulation to submit reports to the Agency or the manufacturer with the exception of certain adverse reactions following immunization with vaccines as mandated by the National Childhood Vaccine Injury Act of 1986 (42 U.S.C. 300aa-1). Reports for vaccines are not submitted via MedWatch or MedWatch forms, but are submitted to the Vaccines Adverse Event Reporting System (see http://vaers.hhs.gov), which is jointly administered by FDA and the Centers for Disease Control and Prevention. Hospitals are not required by Federal law or regulation to submit reports associated with drug products, biological products, or special nutritional products. However, hospitals and other user facilities are required by Federal law to report medical device-related deaths and serious injuries. Under Federal law and regulation, section 761(b)(1) of the FD&C Act, a dietary supplement manufacturer, packer, or distributor whose name appears on the label of a dietary supplement marketed in the United States is required to submit to FDA any serious adverse event report it receives regarding use of the dietary supplement in the United States. However, FDA bears the burden to gather and review evidence that a dietary supplement may be adulterated under section 402 of the FD&C Act (21 U.S.C. 342) after that product is marketed. Therefore, the Agency depends on the voluntary reporting by health professionals, and especially by consumers, of suspected serious adverse events and product quality problems associated with the use of dietary supplements. All dietary supplement reports were previously received by the Agency on paper versions of Form FDA 3500 (or Form FDA 3500B) (by mail or fax). Currently, electronic reports may be sent to the Agency via an online submission route called the Safety Reporting Portal (http://www.safetyreporting.hhs.gov/). In that case, Form FDA 3500 (or Form FDA 3500B) is not used. Form FDA 3500 may be used to report to the Agency serious adverse events, product problems, and product use errors and therapeutic failures. The form is provided in both paper and electronic formats. Reporters may mail or fax paper forms to the Agency (a fillable PDF version of the form is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf) or reporters may electronically submit a report via the MedWatch Online Voluntary Reporting Form (https://www.accessdata.fda.gov/scripts/medwatch/). Reporting is supported for drugs, non-vaccine biologicals, medical devices, special nutritional products, cosmetics, and non-prescription (over the counter (OTC)) human drug products marketed without an approved application. The paper form may also be used to submit reports about tobacco products and dietary supplements. Electronic reports for tobacco products and dietary supplements may be submitted to the Agency via an online submission route called the Safety Reporting Portal (http://www.safetyreporting.hhs.gov/). III. Use of Form 3500B (Consumer Voluntary Reporting) This voluntary version of the form may be used by consumers (i.e. patients and their caregivers) to submit reports not mandated by Federal law or regulation. Individual patients or their caregivers are not required by law or regulation to submit reports to the Agency or the manufacturer. FDA supports and encourages direct reporting to the Agency by consumers of suspected serious adverse outcomes and other product problems associated with human medical products, (http://www.fda.gov/Safety/ReportaProblem/default.htm). Since the inception of the MedWatch program, launched in July 1993 by then FDA Commissioner David Kessler, the program has been promoting and facilitating voluntary reporting by both the general public and healthcare professionals. FDA has further encouraged voluntary reporting by requiring inclusion of the MedWatch toll-free phone number or the MedWatch Internet address on all outpatient drug prescriptions dispensed, as mandated by section 17 of the Best Pharmaceuticals for Children Act (Pub. L. 107-109). On March 25, 2008, section 906 of the Food and Drug Administration Amendments Act (Pub. L. 110-85) amended section 502(n) of the FD&C Act and mandated that published direct-to-consumer advertisements for prescription drugs include the following statement printed in conspicuous text (this includes vaccine products): ``You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch, or call 1-800-FDA-1088.'' Most private vendors of consumer medication information, the drug product-specific instructions dispensed to consumers at outpatient pharmacies, remind patients to report ``side effects'' to FDA and provide contact information to permit reporting via the MedWatch process. Since 2013, FDA has made available Form FDA 3500B. It was proposed during the previous authorization in 2012 and is a version of Form FDA 3500 that is tailored for consumers and written in plain language (in conformance with the Plain Writing Act of 2010 (Pub. L. 111-274) http://www.thefederalregister.org/fdsys/pkg/PLAW-111publ274/pdf/PLAW-111publ274.pdf). Form FDA 3500B evolved from several iterations of draft versions, with input from human factors experts, from other regulatory agencies, and with extensive input from consumer advocacy groups and the general public. Form FDA 3500B may be used to report to the Agency adverse events, product problems, and product use errors. The form is provided in both paper and electronic formats. Reporters may mail or fax paper forms to the Agency (a fillable PDF version of the form is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM349464.pdf) or electronically submit a report via the MedWatch Online Voluntary Reporting Form (https://www.accessdata.fda.gov/scripts/medwatch/). Reporting is supported for drugs, non-vaccine biologicals, medical devices, special nutritional products, cosmetics, and non-prescription OTC human drug products marketed without an approved application. The paper form may also be used to submit reports about tobacco products and dietary supplements. Electronic reports for tobacco products and dietary supplements may be submitted to the Agency via an online submission route called the [[Page 31044]] Safety Reporting Portal (http://www.safetyreporting.hhs.gov/). IV. Use of Form FDA 3500A (Mandatory Version) A. Drug and Biological Products In sections 505(b), 505(j) (21 U.S.C. 354(b) and (j)), 503B, and 704 (21 U.S.C. 374) of the FD&C Act, Congress has required that important safety information relating to all human drug products be made available to the FDA so that it can take appropriate action to protect the public health when necessary. Section 702 of the FD&C Act (21 U.S.C. 372) authorizes investigational powers to the FDA for enforcement of the FD&C Act. These statutory requirements regarding mandatory reporting have been codified by FDA under parts 310 and 314 (drugs) and 600 (biological products). Mandatory reporting of adverse reactions for HCT/Ps has been codified in Sec. 1271.350. B. OTC Monograph Drug Products and Dietary Supplements Section 760 of the FD&C Act provides for mandatory safety reporting for non-prescription human drug products marketed without an approved application as described in the Dietary Supplement and Nonprescription Drug Consumer Protection Act (Pub. L. 109-462), which became law on December 22, 2006. The law requires manufacturers, packers, and distributors of nonprescription, OTC human drug products marketed without an approved application (OTC monograph drug products) to submit reports of adverse experiences from domestic sources. The law also requires reports of serious adverse events to be submitted to FDA by manufacturers of dietary supplements. C. Postmarketing Safety Reports--Changes in Format Starting in June 2015 Current requirements specify that postmarketing adverse experience reports must be submitted on paper on Form FDA 3500A (or the Council for International Organizations of Medical Sciences) I form for serious, unexpected adverse experiences from a foreign source). For the last several years the Agency has accepted electronic submissions in lieu of the paper Form FDA 3500A on the condition they are submitted in a manner that the Agency can process, review, and archive. On June 10, 2014, the Agency issued a final rule entitled ``Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements'' (79 FR 33072) that requires electronic submission of all mandatory postmarketing safety reports, including individual case safety reports. Entities with mandatory reporting obligations under parts 310 and 314 (drugs) and 600 (biological products) and specified under section 760 of the FD&C Act must implement this rule within 1 year of the issuance date (by June 10, 2015). For more information, go to http://www.thefederalregister.org/fdsys/pkg/FR-2014-06-10/pdf/2014-13480.pdf. D. Medical Device Products Section 519 of the FD&C Act (21 U.S.C. 360i) requires manufacturers and importers of devices intended for human use to establish and maintain records, make reports, and provide information, as the Secretary of Health and Human Services may, by regulation, reasonably be required to provide assurance that such devices are not adulterated or misbranded and to otherwise assure its safety and effectiveness. The Safe Medical Devices Act of 1990 (Pub. L. 101-629), signed into law on November 28, 1990, amends section 519 of the FD&C Act. The amendment requires that user facilities such as hospitals, nursing homes, ambulatory surgical facilities, and outpatient treatment facilities report deaths related to medical devices to FDA and to the manufacturer, if known. Serious illnesses and injuries are to be reported to the manufacturer or to FDA if the manufacturer is not known. These statutory requirements regarding mandatory reporting have been codified by FDA under part 803. Part 803 mandates the use of Form FDA 3500A for reporting to FDA on medical devices. The Medical Device User Fee and Modernization Act of 2002 (MDUFMA) (Pub. L. 107-250), signed into law October 26, 2002, amended section 519 of the FD&C Act. The MDUFMA amendment (section 303) required FDA to revise the MedWatch forms to facilitate the reporting of information relating to reprocessed single-use devices, including the name of the re-processor and whether the device has been reused. V. Proposed Modifications to Existing Forms FDA 3500, 3500A, and 3500B A. General Changes The proposed modifications to Forms FDA 3500 and 3500A reflect changes that will bring the forms into conformation, since the previous authorization in 2012, with current regulations, rules, and guidances. B. Changes Proposed for Form FDA 3500 Formatting modifications are proposed to several fields to enhance the clarity and utility of the information collected. In section A2, it is proposed that checkboxes for years, months, weeks, and days be added to permit clarity about the age of the patient. In section A4, it is proposed that checkboxes for pounds (lb) and kilograms (kg) be added to permit clarity about the patient's weight. To permit clarity and utility for the dates being reported, it is proposed that field labels and instructions be modified to ask the reporter to use the format DD- MMM-YYYY. A watermark will be added to the date fields to prompt the reporter to enter data using this format. This proposed change will reduce the data-entry burden for FDA by making the form more easily scanned by the optical character recognition (OCR) software used by the Agency. This change is proposed for all of the date fields on the form including: A2 (Date of Birth), B2 (Death), B3, B4, C (Returned to Manufacturer On), D7, E4 (Expiration Date), E6, and E7. In recognition of OMB 1997 Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity, and as part of FDA's Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data (http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/UCM410474.pdf) developed in response to the requirement in section 907 of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 (Pub. L.112- 144), changes are proposed to the location and formatting of the fields containing data about the patient's race. It is proposed that race be deleted from the descriptor in section B, field B7, that requests ``Other Relevant History, Including Preexisting Medical Conditions (e.g. allergies, race, pregnancy, smoking and alcohol use, liver/kidney problems, etc.).'' Instead, it is proposed that a new race and ethnicity field be added to section A, ``Patient Information.'' The proposed ethnicity field will be numbered 5a and state ``Ethnicity (Check single best answer)'' with corresponding checkboxes for ``Hispanic/Latino'' and ``Not Hispanic/Latino.'' Adjacent to this field, the ``Race'' field will be numbered 5b and state ``Race (Check all that apply).'' It will contain checkboxes for ``Asian,'' ``American Indian or Alaskan Native,'' ``Black or African American,'' [[Page 31045]] ``White,'' and ``Native Hawaiian or Other Pacific Islander.'' Changes are proposed to the location, formatting, and labeling of fields related to the suspect product and its availability for evaluation to allow the product's identifying information to be grouped in one place, and increase the likelihood that this information is entered. In section D, field D1 will be used to request data for ``Name and Strength,'' ``Manufacturer/Compounder,'' as well as ``Lot #,'' and ``NDC # or Unique ID #'' for up to two suspect medical products. In 2013, the Drug Quality and Security Act (Pub. L. 113-54) added new section 503B to the FD&C Act, under which a compounder may elect to become an outsourcing facility by registering with FDA. Outsourcing facilities are required to report adverse events to FDA in accordance with the content and format requirements established through guidance or regulation under Sec. 310.305. In addition to mandatory reporting, many adverse events related to compounded drugs are reported voluntarily by healthcare professionals and consumers. Therefore, FDA is proposing changes to the voluntary versions of the MedWatch forms (i.e. Forms FDA 3500 and 3500B) to improve the ability to rapidly identify reports involving compounded drugs. The existing field (section D, field D1) that contains the descriptor ``Manufacturer'' will be relabeled ``Manufacturer/Compounder.'' Correspondingly, a checkbox for ``Manufacturer/Compounder'' will be added to the existing field (section G, field G4) ``Also Reported to.'' It is proposed that a new field be added to the section entitled ``Suspect Products.'' The new field will be numbered and include a descriptor ``Is the Product Compounded?'' with corresponding checkboxes for ``Yes'' or ``No.'' The new field will also include a descriptor ``Is the Product Over- the-Counter'' with corresponding checkboxes for ``Yes'' or ``No.'' The instructions to the form will be updated accordingly. The form remains a three-page form with all the main data fields on page one, with instructions for use and a self-addressed, postage-paid return mailer on the reverse side of page one, and page three being a continuation page for additional information should reporters need extra space. C. Changes Proposed for Form FDA 3500A Formatting modifications are proposed to several fields to enhance the clarity and utility of the information collected. In section A2, it is proposed that checkboxes for years, months, weeks, and days be added to permit clarity about the age of the patient. In section A4, it is proposed that checkboxes for pounds (lb) and kilograms (kg) be added to permit clarity about the patient's weight. To permit clarity and utility for the dates being reported, it is proposed that field labels and instructions be modified to ask the reporter to use the format DD- MMM-YYYY. A watermark will be added to the date fields to prompt the reporter to enter data using this format. This proposed change will reduce the data-entry burden for FDA by making the form more easily scanned by the OCR software used by the Agency. This change is proposed for all of the date fields on the form including: A2 (Date of Birth), B2 (Death), B3, B4, C7, D4 (Expiration Date), D6, D7, D10 (Returned to Manufacturer on), F6, F8, F11, F13, G4, and H4. In recognition of OMB's 1997 Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity, and as part of FDA's Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data (http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/UCM410474.pdf) developed in response to the requirement in section 907 of FDASIA, changes are proposed to the location and formatting of the fields containing data about the patient's race. It is proposed that race be deleted from the descriptor in section B, field B7, that requests ``Other Relevant History, Including Preexisting Medical Conditions (e.g. allergies, race, pregnancy, smoking and alcohol use, liver/kidney problems, etc.).'' Instead, it is proposed that a new race and ethnicity field be added to section A, ``Patient Information.'' The proposed ethnicity field will be numbered 5a, and state ``Ethnicity (Check single best answer)'' with corresponding checkboxes for ``Hispanic/Latino'' and ``Not Hispanic/Latino.'' Adjacent to this field, the ``Race'' field will be numbered 5b, and state ``Race (Check all that apply).'' It will contain checkboxes for ``Asian,'' ``American Indian or Alaskan Native,'' ``Black or African American,'' ``White,'' and ``Native Hawaiian or Other Pacific Islander.'' Changes are proposed to the location, formatting, and labeling of fields related to the suspect product and its availability for evaluation to allow the product's identifying information to be grouped in one place and increase the likelihood that this information is entered. For consistency and clarity, it is proposed that many of the fields in the suspect products sections on Forms FDA 3500 and 3500A be mirrored. For Form FDA 3500A, it is proposed that the current section C, field C1, ``Name (Give labeled strength & mfr/labeler),'' also be used to request data for ``Lot #'' and ``NDC # or Unique ID #.'' Section C, field C1 will be relabeled ``Name, Manufacturer/Compounder, Strength.'' Proposed field C1 will contain distinct areas for ``Name and Strength,'' ``Manufacturer/Compounder,'' ``NDC # or Unique ID #,'' and ``Lot #'' for up to two suspect products. Since the information will now be captured in proposed field C1, separate fields for ``Lot #'' and ``NDC #/Unique ID #'' (C6 and C9 from the current form) will not be needed. The currently numbered field C2, ``Dose, Frequency & Route Used,'' will be renumbered C3. It will also be reformatted to have three distinct areas for dose, frequency, and route, respectively, for up to two suspect products. Current field C3, ``Therapy Dates,'' will be renumbered C4, and current field C4, ``Diagnosis for Use,'' will be renumbered C5. Current field C5, ``Event Abated After Use Stopped or Dose Reduced,'' will be renumbered C9, and field C8, ``Event Reappeared After Reintroduction?'' will be renumbered C10. The field for expiration date will be renumbered C8, and the field for concomitant medical products and therapy dates (current field C10) will be renumbered C2. As stated previously, in 2013, the Drug Quality and Security Act added new section 503B to the FD&C Act, under which a compounder may elect to become an outsourcing facility by registering with FDA. Outsourcing facilities are required to report adverse events to FDA in accordance with the content and format requirements established through guidance or regulation under Sec. 310.305. To facilitate implementation of this mandatory reporting requirement, changes will need to be made to the existing Form FDA 3500A. It is proposed that a new field be added to section G1 that contains the descriptor ``Compounding Outsourcing Facility 503B?'' with a corresponding checkbox for ``Yes.'' It is also proposed that a new field be added to section C, ``Suspect Products.'' The new field will be numbered C6 and include a descriptor ``Is the Product Compounded?'' with corresponding checkboxes for ``Yes'' or ``No'' (for up to two suspect products). The instructions to the form will be updated accordingly. In addition, a new field numbered C7 will be added and ``Is the Product Over-the-Counter?'' with corresponding [[Page 31046]] checkboxes for ``Yes'' or ``No'' (for up to two suspect products). The instructions to the form will be updated accordingly. Additionally, for clarity, in section G, field G5, the area labeled ``(A)NDA #'' will be split into two separate areas--one for ``ANDA #'' and one for ``NDA #.'' D. Changes Proposed for Form FDA 3500B For consistency, and to improve the quality of the data received, the changes being proposed on the voluntary Form FDA 3500 (for use by healthcare professionals) are also being proposed on the voluntary Form FDA 3500B (for use by consumers). Formatting modifications are being proposed to several fields to enhance the quality, utility, and clarity of the information. In section D, the field entitled ``Age (at time the problem occurred) or Birth Date'' will be separated into separate fields for age and date of birth. In the field for ``Age,'' checkboxes for years, months, weeks, and days will be added to permit clarity about the age of the patient. Similarly, for the field in section D labeled ``Weight,'' checkboxes for pounds (lb) and kilograms (kg) will be added to permit clarity about the patient's weight. The instructions will be modified accordingly. To permit clarity about the dates being reported, field labels and instructions will be modified to ask the reporter to use the format DD-MMM-YYYY. A watermark will be added to the field to prompt the reporter to respond using this format. This will also reduce the data entry burden by making the form more easily scanned by the OCR software used by FDA. All of the date fields on the form will be affected by this proposed change. These include section A (date the problem occurred, death), section B (expiration date, date the person first started taking or using this product, date the person stopped taking or using this product), section C (date the implant was put in, date the implant was taken out), section D (date of birth), and section E (today's date). A formatting modification to the field in section D that is currently labeled ``Race'' is being proposed in recognition of OMB 1997 Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity, and as part of FDA's Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data (http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/UCM410474.pdf) developed in response to the requirement in section 907 of FDASIA. It is proposed that the field be relabeled ``Race (Check all that apply)'' and contain checkboxes for ``Asian,'' ``American Indian or Alaskan Native,'' ``Black or African American,'' ``White,'' and ``Native Hawaiian or Other Pacific Islander.'' It is also proposed that the field contain an adjacent area labeled ``Ethnicity (Check single best answer)'' with corresponding checkboxes for ``Hispanic/Latino'' and ``Not Hispanic/Latino.'' As discussed previously in this notice, many adverse events related to compounded drugs are reported voluntarily by healthcare professionals and consumers. Therefore, FDA is proposing changes to the voluntary versions of Forms FDA 3500 and 3500B to improve the Agency's ability to rapidly identify reports involving compounded drugs. FDA proposes to add a field to section B with the label ``Is the Product Compounded?'' and corresponding checkboxes for ``Yes'' or ``No.'' FDA also proposes to add a field to section B with the label ``Is the Product Over-the-Counter'' with corresponding checkboxes for ``Yes'' or ``No.'' Finally, to improve clarity and to be consistent with Form FDA 3500, FDA proposes to reword the last field of section E that currently asks ``May we give your name and contact information to the company that makes the product (manufacturer) to help them evaluate the product?'' to ``If you do NOT want your identity disclosed to the manufacturer, place an `X' in this box.'' Items that we proposed in the 60-day notice that have changed: The proposed change to Form FDA 3500 to merge sections C and D has been retracted; therefore, the sections will not be re-sequenced on Form FDA 3500. For the proposed new field ``Is product compounded or over-the- counter'' (proposed on Forms FDA 3500, 3500A and 3500B), the descriptor ``Check all that apply'' will be deleted and these will be broken out into two separate questions, in two separate fields, with corresponding ``Yes'' and ``No'' checkboxes for up to two suspect products. The proposal to add a new ``compounder'' checkbox to Form 3500 Field G4 has been retracted. Instead the existing manufacturer checkbox will be relabeled ``manufacturer/compounder.'' The proposal to add a new field ``Product Available for Evaluation?'' to the ``suspect products'' section of the Form FDA 3500A was retracted. The proposed changes outlined above reflect these differences. We have reviewed the name address field for Forms FDA 3500 and 3500A and believe data quality would be improved if separate fields for last name, first name, address, state, ZIP code, and Country were also included instead of one field labeled ``name and address'' to capture all of that information. In the Federal Register of December 11, 2014 (79 FR 73591), FDA published a 60-day notice requesting public comment on the proposed collection of information. Four comments were received. Comments Affecting All Three FDA Forms (3500, 3500A, 3500B) (Comment 1) One commenter recommended the option of an ``unknown'' check box for race/ethnicity. (Response) FDA disagrees with this comment as it is inconsistent with the OMB standards for the classification of Federal data on race and ethnicity. (Comment 2) One commenter requested an implementation date of 18 months after publication of the finalized form. (Response) FDA will allow sufficient time for implementation. Comments Affecting FDA Forms 3500 and 3500A (Comment 1) Section G Field 4 and Section C Field 6: We propose to add a third checkbox labeled ``unknown'' for when this type of information is not received. Rationale: This information may not be received. (Response) FDA disagrees. G4 corresponds to ``Date Received by Manufacturer'' on Form FDA 3500A. This is a required element and the manufacturer should always have this information. C6 corresponds to Lot # on the existing Form FDA 3500A. If this information is unknown the field should be left blank. (Comment 2) In Section A1: Along with Patient Identifier, in bracket (first, last) can be added for better identification. (Response) FDA disagrees. Capturing this data may discourage people from submitting voluntary reports. The instructions for the form state ``Do not use the patient's name or social security number.'' (Comment 3) In Section A2, Age group can be added. (Response) FDA disagrees. The WG believes that the two data elements proposed for age--Age with checkboxes for days, weeks, months, years, and date of birth in the format DD-MMM-YYYY are sufficient to capture this data. (Comment 4) In Section A3, after selecting Female, a check box should populate for pregnancy with options Yes, No, UNK. Pregnancy can be removed from section B7. [[Page 31047]] (Response) FDA disagrees. The Agency believes pregnancy status is captured sufficiently well through existing field B7. (Comment 5) In Section B1, if Product problem check box is selected then only a text box to enter NDC# should come as National Drug Code is required ONLY when reporting a drug product problem. It can be removed from C9. (Response) FDA disagrees. Product problem is not limited to drug products, and may include medical devices, biologics, and other products which would not have an associated NDC number. (Comment 6) In section B2, Hospitalization--initial or prolonged can be relabeled to only Hospitalization and can have three check boxes; Initial, Prolonged and Hospital discharge summary available. Reporter can select whichever is applicable. (Response) FDA Disagrees. We encourage reporters to put more detail about the hospitalization in the narrative text. (Comment 7) In section B5, Describe Event or Problem, along with individual event terms, seriousness criteria for each event should be populated, so that event-wise seriousness criteria can be identified. (Response) FDA disagrees. An event is considered serious if it meets the regulatory definition, as outlined in Sec. Sec. 310.305, 314.80, 600.80, 803.3, and 1271. Comments Affecting Form FDA 3500 None. Comments Affecting Form FDA 3500A (Comment 1) Action taken with drug can be added in section C. (Response) FDA disagrees. This information equates to product use stopped or dose reduced, which is already captured on Forms FDA 3500 and 3500A. (Comment 2) We propose that the FDA require medical device adverse reporting use the MedDRA dictionary instead of the Patient Problem Codes. Rationale: Currently when reporting adverse events for medical devices, the current dictionary used is the ``Patient Problem Codes of the Center for Devices and Radiological Health.'' This dictionary is much smaller (~800 terms) than the widely used MedDRA dictionary used when reporting adverse events with drugs (~20.6K terms). Using the MedDRA dictionary in place of the Patient Problem Codes would allow for more accurate recording of patient adverse events. (Response) FDA disagrees. FDA will continue to use Patient Problem Codes for medical devices instead of MedDRA coding. While the MedDRA dictionary is able to adequately capture adverse events with drugs, patient problem codes and device problem codes are more effective at capturing device related adverse events. (Comment 3) Causality scale can be added in Section C. (Response) FDA Disagrees. Causality is not assessed at the reporting level. Refer to Sec. Sec. 310.305(g), 314.80(k), 600.80(k)(1), and 803.16. (Comment 4) In section C10, Concomitant Medical Products and Therapy Dates (Exclude treatment of event), Dose of concomitant drugs should also be included. (Response) FDA disagrees. Concomitant medical products are not limited to drug products, and may include medical devices, biologics, and other regulated products. As concomitant products are not suspected to be related to the adverse event, it is not necessary to capture the dose. (Comment 5) In Section E1, along with Phone#, Email address can also be included. (Response) FDA disagrees. Form FDA 3500A, section E already includes a field for email address, as does Forms FDA 3500, section G, and 3500B. However, we have reviewed the name address field for Forms FDA 3500 and 3500A and believe data quality would be improved if separate fields for last name, first name, address, state, ZIP code, and Country were also included instead of one field labeled ``name and address'' to capture all of that information. Comments Affecting Form 3500B (Comment 1) One commenter urged the inclusion of a Spanish version of Form FDA 3500B. (Response) FDA agrees with the importance of communicating the benefits and risks of medical products to healthcare providers and patients, especially underrepresented populations, including those with limited English proficiency. FDA's language access plan (http://www.fda.gov/ForConsumers/ByAudience/MinorityHealth/ucm412582.htm) outlines some of the steps FDA is taking to improve communications with underrepresented populations. FDA's drug safety communications are currently translated into Spanish and are available at http://www.fda.gov/Drugs/DrugSafety/ucm263010.htm. FDA is also working to improve the quality of the data received in adverse event reports received directly from consumers. At this time, FDA plans to focus resources on improving data quality from English-language consumer reports before evaluating how to best handle product experience information from non-English speaking consumers. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Reporting Burden -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of FDA center/21 CFR section/FDA form Number of responses per Total annual Average burden per response Total respondents respondent responses -------------------------------------------------------------------------------------------------------------------------------------------------------- Center for Biologics Evaluation and Research/ Center for Drug Evaluation and Research: Form FDA 3500............................ 14,727 1 14,727 0.66 (40 minutes)........................ 9,720 Form FDA 3500A (Sec. Sec. 310.305, 599 98 58,702 1.21..................................... 71,029 314.80, 314.98, 600.80, 1271.350). Form FDA 3500A (Sec. 310.305 50 2 100 1.21..................................... 121 outsourcing facilities). Center for Devices and Radiological Health: Form FDA 3500............................ 5,233 1 5,233 0.66 (40 minutes)........................ 3,454 Form 3500A (Sec. 803).................. 2,277 296 673,992 1.21..................................... 815,530 Center for Food Safety and Applied Nutrition: Form FDA 3500............................ 1,793 1 1,793 0.66 (40 minutes)........................ 1,183 Form 3500A............................... 1,659 1 1,659 1.21..................................... 2,007 Center for Tobacco Products Form FDA 3500.... 39 1 39 0.66 (40 minutes)........................ 26 [[Page 31048]] All Centers Form FDA 3500B................... 13,750 1 13,750 0.46 (30 minutes)........................ 6,325 ---------------------------------------------------------------------------------------------------------- Total.................................... .............. .............. .............. ......................................... 909,395 -------------------------------------------------------------------------------------------------------------------------------------------------------- Dated: May 27, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015-13102 Filed 5-29-15; 8:45 am] BILLING CODE 4164-01-P
![31042 Federal Register / Vol. 80, No. 104 / Monday, June 1, 2015 / Notices
representative from the government of V. Comments in brackets in the heading of this
Canada, one representative from the Interested persons may submit either document.
industry of Canada, one representative electronic comments regarding this FOR FURTHER INFORMATION CONTACT: FDA
from the government of South Africa, document to http://www.regulations.gov PRA Staff, Office of Operations, Food
and one representative from the or written comments to the Division of and Drug Administration, 8455
industry of South Africa. The VICH Dockets Management (see ADDRESSES). It Colesville Rd., COLE–14526, Silver
Secretariat, which coordinates the is only necessary to send one set of Spring, MD 20993–0002, PRAStaff@
preparation of documentation, is comments. Identify comments with the fda.hhs.gov.
provided by the International docket number found in brackets in the SUPPLEMENTARY INFORMATION: In
Federation for Animal Health (IFAH). heading of this document. Received
An IFAH representative also compliance with 44 U.S.C. 3507, FDA
comments may be seen in the Division has submitted the following proposed
participates in the VICH Steering of Dockets Management between 9 a.m.
Committee meetings. collection of information to OMB for
and 4 p.m., Monday through Friday, and review and clearance.
II. Draft Guidance on Studies To will be posted to the docket at http://
www.regulations.gov. MedWatch: The FDA Medical Products
Evaluate the Safety of Residues of
Reporting Program OMB Control
Veterinary Drugs in Human Food: VI. Electronic Access Number 0910–0291—Extension
General Approach To Establish an
Acute Reference Dose (ARfD) Persons with access to the Internet I. Background
may obtain the draft guidance at either
The VICH Steering Committee held a http://www.fda.gov/AnimalVeterinary/ To ensure the marketing of safe and
meeting in February 2015 and agreed GuidanceComplianceEnforcement/ effective products, it is critical that
that the draft guidance document GuidanceforIndustry/default.htm or postmarketing adverse outcomes and
entitled ‘‘Studies to Evaluate the Safety http://www.regulations.gov. product problems are reported for all
of Residues of Veterinary Drugs in FDA-regulated human healthcare
Dated: May 27, 2015. products, including drugs (prescription
Human Food: General Approach to Leslie Kux,
Establish an Acute Reference Dose and nonprescription), biologics, medical
Associate Commissioner for Policy. devices, dietary supplements and other
(ARfD)’’ (VICH GL54) should be made
available for public comment. This draft [FR Doc. 2015–13105 Filed 5–29–15; 8:45 am] special nutritional products (e.g. infant
VICH guidance document is intended to BILLING CODE 4164–01–P formula and medical foods), and
address the nature and types of data that cosmetics. To facilitate reporting on
can be useful in determining an ARfD human medical products (except
DEPARTMENT OF HEALTH AND vaccines) during their postapproval and
for residues of veterinary drugs, the
HUMAN SERVICES marketed lifetimes, three forms
studies that may generate such data, and
(collectively known as the MedWatch
how the ARfD may be calculated based Food and Drug Administration forms) are available from the Agency.
on these data.
[Docket No. FDA–2014–N–1960] Form FDA 3500 is intended to be used
FDA and the VICH Expert Working for voluntary (i.e., not mandated by law
Group will consider comments about Agency Information Collection or regulation) reporting by healthcare
the draft guidance document. Activities; Submission for Office of professionals. Form FDA 3500B is
III. Significance of Guidance Management and Budget Review; written in plain language and is
Comment Request; MedWatch: The intended to be used for voluntary
This draft guidance, developed under Food and Drug Administration Medical reporting (i.e., not mandated by law or
the VICH process, has been revised to Products Reporting Program regulation) by consumers (i.e., patients
conform to FDA’s good guidance and their caregivers). Form FDA 3500A
practices regulation (21 CFR 10.115). AGENCY: Food and Drug Administration, is used for mandatory reporting (i.e.,
The draft guidance, when finalized, will HHS. required by law or regulation). When
represent the current thinking of FDA ACTION: Notice. FDA receives this information from
on Studies to Evaluate the Safety of healthcare professionals, patients, or
Residues of Veterinary Drugs in Human SUMMARY: The Food and Drug
Administration (FDA) is announcing consumers, the report becomes data that
Food: General Approach to Establish an will be used to assess and evaluate the
Acute Reference Dose (ARfD). It does that a proposed collection of
information has been submitted to the risk associated with the product. FDA
not establish any rights for any person will then take whatever action is
and is not binding on FDA or the public. Office of Management and Budget
(OMB) for review and clearance under necessary to reduce, mitigate, or
You can use an alternative approach if eliminate the public’s exposure to the
it satisfies the requirements of the the Paperwork Reduction Act of 1995.
risk through regulatory and public
applicable statutes and regulations. DATES: Fax written comments on the
health interventions.
collection of information by July 1,
IV. Paperwork Reduction Act of 1995 2015. Authorizing Statutes and Codified
This draft guidance refers to ADDRESSES: To ensure that comments on Regulations
previously approved collections of the information collection are received, The Federal Food, Drug, and Cosmetic
information found in FDA regulations. OMB recommends that written Act (the FD&C Act) (21 U.S.C. 353b,
These collections of information are comments be faxed to the Office of 355, 360i, 360l, and 393) and the Public
Lhorne on DSK2VPTVN1PROD with NOTICES
subject to review by the Office of Information and Regulatory Affairs, Health Service Act (42 U.S.C. 262)
Management and Budget (OMB) under OMB, Attn: FDA Desk Officer, FAX: represent the statutory authority for the
the Paperwork Reduction Action of 202–395–7285, or emailed to oira_ FDA to collect mandatory adverse event
1995 (44 U.S.C. 3501–3520). The submission@omb.eop.gov. All reports from regulated industry on
collections of information in 21 CFR comments should be identified with the medical products once approved for
part 514 have been approved under OMB control number 0910–0291. Also marketing to monitor the safety of drugs,
OMB control number 0910–0032. include the FDA docket number found biologics, medical devices, and dietary
VerDate Sep<11>2014 14:50 May 29, 2015 Jkt 235001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\01JNN1.SGM 01JNN1](https://thefederalregister.org/doc/80_FR_31146/page/1.svg)
![31048 Federal Register / Vol. 80, No. 104 / Monday, June 1, 2015 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN—Continued
Number of Average
Number of Total annual
FDA center/21 CFR section/FDA form responses per burden per Total
respondents responses
respondent response
All Centers Form FDA 3500B ..................................... 13,750 1 13,750 0.46 (30 minutes) ... 6,325
Total ...................................................................... ........................ ........................ ........................ ................................ 909,395
Dated: May 27, 2015. Building 1, where routine security include participation of FDA review
Leslie Kux, checks will be performed. For parking divisions, the relevant patient
Associate Commissioner for Policy. and security information, please refer to communities, and other interested
[FR Doc. 2015–13102 Filed 5–29–15; 8:45 am] http://www.fda.gov/AboutFDA/ stakeholders.
BILLING CODE 4164–01–P
WorkingatFDA/BuildingsandFacilities/ On April 11, 2013, FDA published a
WhiteOakCampusInformation/ notice in the Federal Register (78 FR
ucm241740.htm. 21613) that announced the disease areas
DEPARTMENT OF HEALTH AND Submit electronic comments to for meetings in fiscal years (FY) 2013–
HUMAN SERVICES http://www.regulations.gov. Submit 2015, the first 3 years of the 5-year
written comments to the Division of PDUFA V timeframe. The Agency used
Food and Drug Administration Dockets Management (HFA–305), Food several criteria outlined in the April 11,
and Drug Administration, 5630 Fishers 2013, notice to develop the list of
[Docket No. FDA–2015–N–1798]
Lane, rm. 1061, Rockville MD 20852. disease areas. FDA obtained public
Patient-Focused Drug Development for All comments should be identified with comment on the Agency’s proposed
Alpha-1 Antitrypsin Deficiency; Public the docket number found in brackets in criteria and potential disease areas
Meeting the heading of this document. through a public docket and a public
FOR FURTHER INFORMATION CONTACT: meeting that was convened on October
AGENCY: Food and Drug Administration, Barbara Kass, Center for Biologics 25, 2012. In selecting the set of disease
HHS. Evaluation and Research, Food and areas, FDA carefully considered the
ACTION: Notice of public meeting; Drug Administration, 10903 New public comments received and the
request for comments. Hampshire Ave., Bldg. 71, rm. 1125, perspectives of review divisions at FDA.
Silver Spring, MD 20993, 240–402– FDA has initiated a second public
SUMMARY: The Food and Drug process for determining the disease
6887, FAX: 301–595–1243, email:
Administration (FDA or Agency) is areas for meetings in FY 2016–2017 and
PatientFocused_CBER@fda.hhs.gov.
announcing a public meeting and an published a notice in the Federal
SUPPLEMENTARY INFORMATION:
opportunity for public comment on Register on October 8, 2014 (79 FR
Patient-Focused Drug Development for I. Background on Patient-Focused Drug 60857). More information, including the
Alpha-1 Antitrypsin Deficiency (AATD). Development list of disease areas and a general
Patient-Focused Drug Development is FDA has selected AATD as the focus schedule of meetings, is posted on
an FDA performance commitment under of a public meeting under the Patient- FDA’s Web site at http://www.fda.gov/
the fifth authorization of the Focused Drug Development initiative. ForIndustry/UserFees/
Prescription Drug User Fee Act (PDUFA This initiative involves obtaining a PrescriptionDrugUserFee/
V). The public meeting is intended to better understanding of patients’ ucm326192.htm.
provide FDA with patients’ perspectives perspectives on the challenges posed by
on the impact on daily life of AATD. AATD and the impact of current II. Purpose and Scope of the Meeting
FDA also is seeking patients’ therapies for this condition. The Patient- The purpose of this Patient-Focused
perspectives on the available therapies Focused Drug Development initiative is Drug Development meeting is to obtain
for this disorder. being conducted to fulfill FDA input on the symptoms and other
DATES: The public meeting will be held performance commitments that are part impacts that matter most to patients
on September 29, 2015, from 9 a.m. to of the PDUFA reauthorization under with AATD. FDA also intends to seek
3:30 p.m. Registration to attend the Title I of the Food and Drug patients’ perspectives on current
meeting must be received by September Administration Safety and Innovation approaches to treating this disorder.
15, 2015. Registration from those Act (Pub. L. 112–144). The full set of FDA expects that this information will
individuals interested in presenting performance commitments is available come directly from patients, caregivers,
comments as part of the panel on the FDA Web site at http:// and patient advocates.
discussions should be received by July www.fda.gov/downloads/forindustry/ Individuals with AATD have low
31, 2015. See the SUPPLEMENTARY userfees/prescriptiondruguserfee/ serum levels of Alpha-1-Antitrypsin
INFORMATION section for instructions on ucm270412.pdf. (AAT, also known as Alpha-1 proteinase
how to register for the meeting. Submit FDA has committed to obtaining the inhibitor (A1–PI)) and increased risks of
either electronic or written comments patient perspective on 20 disease areas developing a form of chronic obstructive
by November 30, 2015. during the course of PDUFA V. For each lung disease called emphysema and,
Lhorne on DSK2VPTVN1PROD with NOTICES
ADDRESSES: The public meeting will be disease area, the Agency will conduct a less frequently, liver disease. Some
held at the FDA White Oak Campus, public meeting to discuss the disease AATD patients with emphysema have
10903 New Hampshire Ave., Building and its impact on patients’ daily lives, symptoms of asthma. There are different
31 Conference Center, the Great Room the types of treatment benefits that genetic forms of the disease, but even
(rm. 1503), Silver Spring, MD 20993. matter most to patients, and patients’ among people with the same genetic
Entrance for public meeting participants perspectives on the adequacy of the form and similar levels of AAT in their
(non-FDA employees) is through available therapies. These meetings will blood, there is tremendous diversity in
VerDate Sep<11>2014 14:50 May 29, 2015 Jkt 235001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\01JNN1.SGM 01JNN1](https://thefederalregister.org/doc/80_FR_31146/page/7.svg)
Document Created: 2015-12-15 15:19:02
Document Modified: 2015-12-15 15:19:02
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Fax written comments on the collection of information by July 1, 2015. | |
| Contact | FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, [email protected] | |
| FR Citation | 80 FR 31042 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR